# Andy Kidd

> Andy Kidd is the chief executive officer of Tentarix Biotherapeutics, a San Diego company building conditionally active multispecific biologics for oncology and autoimmune disease through its Tentacles platform. A physician turned operator, he carries an unusual pairing of credentials - an M.D. from Oxford and a CFA - and spent over two decades crossing from the consulting room into the boardroom, from Boston Consulting Group to Baxter International to the helm of Nasdaq-listed Aptinyx, which he took public. He stepped into the Tentarix CEO seat in April 2024 to scale a science-heavy startup backed by partnerships with Gilead and AbbVie.

- **Role:** Chief Executive Officer at Tentarix Biotherapeutics
- **Organizations:** Tentarix Biotherapeutics, Aptinyx, Baxter International, The Boston Consulting Group, MATTER
- **Nationality:** United States
- **Education:** M.D., University of Oxford, B.A. in Medical Sciences, University of Cambridge, Chartered Financial Analyst (CFA), CFA Institute
- **Known for:** Led Aptinyx through its initial public offering on Nasdaq, Advanced multiple Aptinyx CNS programs into clinical development, Holds both an M.D. (Oxford) and a CFA designation - a rare combination of clinical and financial expertise

## Career timeline

- **Early career** — Began with The Boston Consulting Group's healthcare practice, working from London and Chicago
- **Mid career** — Held senior leadership roles at Baxter International (NYSE: BAX) across general management and corporate development
- **—** — President and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech; led its IPO and advanced multiple programs into clinical trials
- **2024** — Appointed Chief Executive Officer of Tentarix Biotherapeutics on April 23, 2024

## Achievements

- Led Aptinyx through its initial public offering on Nasdaq
- Advanced multiple Aptinyx CNS programs into clinical development
- Holds both an M.D. (Oxford) and a CFA designation - a rare combination of clinical and financial expertise
- Appointed CEO of Tentarix to execute on partnered programs with Gilead and AbbVie

## Latest updates

- **2024-04** — Named Chief Executive Officer of Tentarix Biotherapeutics, succeeding the founding leadership to scale the company's partnered pipeline.

## Links

- Website: https://tentarix.com
- LinkedIn: http://www.linkedin.com/in/andy-kidd-3678723

---

Profile page: https://yespress.io/andy-kidd
Published by YesPress — https://yespress.io
Last updated: 2026-06-14